ESPR Esperion Therapeutics Inc

Esperion (Nasdaq: ESPR) today announced that Sheldon Koenig, President and CEO, will ring the Nasdaq Stock Market (Nasdaq) opening bell at 9:30 a.m. ET today, April 1, 2024, to commemorate the U.S. Food and Drug Administration’s (FDA) recent approval of broad new labels for Esperion’s products.

“We are honored to ring the Nasdaq opening bell to celebrate a significant milestone for Esperion,” said Mr. Koenig. “This ceremony marks an opportunity to recognize the progress our team has made in achieving these broad new labels, which will significantly reduce previously existing prescribing limitations. I’m pleased to be joined today by other members of our talented team, who have shown unwavering commitment to Esperion throughout this process and helped to get us to where we are now. With these new labels under our belt, we look forward to enabling millions more patients to achieve their LDL-cholesterol goals and ultimately prevent cardiovascular events.”

The event will be live streamed from the Nasdaq MarketSite Tower in New York City and available on Nasdaq’s X and Facebook pages.

Esperion TherapeuticsAt Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life’s work. For more information, visit esperion.com and esperionscience.com and follow us on Twitter at twitter.com/EsperionInc.

Forward-Looking Statements This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization plans, current and planned operational expenses, future operations, commercial products, clinical development, including the timing, designs and plans for the CLEAR Outcomes study and its results, plans for potential future product candidates, financial condition and outlook, including expected cash runway, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Esperion’s actual results to differ significantly from those projected, including, without limitation, the net sales, profitability, and growth of Esperion’s commercial products, clinical activities and results, supply chain, commercial development and launch plans, the outcomes and anticipated benefits of legal proceedings and settlements, and the risks detailed in Esperion’s filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Esperion disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.

Esperion Contact Information: Investors:  Alexis Callahaninvestorrelations@esperion.com(406) 539-1762   Media:  Tiffany Aldrich  corporateteam@esperion.com(616) 443-8438